Midostaurin: the first drug to receive approval for AML since 2000

Midostaurin is a tyrosine kinase inhibitor that has been newly approved for the treatment of acute myeloid leukemia (AML). In this interview, Arnold Ganser, MD, from the Hannover Medical School, Hanno... Author: VJOncology Added: 05/17/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts